High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia

D. A. Van Echo, P. H. Wiernik, J. Aisner

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Thirteen patients with relapsed acute leukemia, 12 adults with acute nonlymphocytic leukemia, and one child with acute lymphoblastic leukemia were treated with VP 16-213, an epipodophyllotoxin analog, at a dose of 200-300 mg/m2/day x5 as a 2-hour intravenous infusion. Only four patients achieved bone marrow aplasia and three regenerated with leukemic cells. The fourth patient achieved a partial remission for 4 weeks. Toxicities included myelosuppression (WBC nadir 500/μl), nausea and vomiting (70% of courses), mucositis (23%), esophagitis (12%), which contributed to death in one patient, hypotension (12%), and transient liver function abnormalities (12%). It is concluded that increasing the dose of VP 16-213 as employed in this study did not increase the therapeutic activity of VP 16-213 for the treatment of relapsed leukemia but did increase the risk of toxicity.

Original languageEnglish (US)
Pages (from-to)325-328
Number of pages4
JournalCancer clinical trials
Volume3
Issue number4
StatePublished - 1980
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint

Dive into the research topics of 'High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia'. Together they form a unique fingerprint.

Cite this